Skip to main content
. 2021 Apr 21;78(14):1294–1308. doi: 10.1093/ajhp/zxab160

Table 7.

Biosimilar Expenditures by US Clinics and Nonfederal Hospitals in 2020

Setting andOriginator Drug 2020 Expenditures
($ Thousands)
Percent Change From 2019
Clinics
 Pegfilgrastim 738,660 30.20
 Infliximab 343,110 39.30
 Filgrastim 121,195 –5.54
 Bevacizumab 868,589 966.98
 Epoetin alfa 155,572 94.17
 Trastuzumab 696,991 808.97
 Rituximab 492,592 . . .a
Nonfederal hospitals
 Pegfilgrastim 135,418 –3.78
 Filgrastim 94,127 –3.23
 Infliximab 89,694 8.30
 Epoetin alfa 137,903 78.59
 Bevacizumab 118,329 1,053.74
 Trastuzumab 91,230 830.30
 Rituximab 138,683 . . .a

aNegligible sales in 2019.